Quest Diagnostics Inc (DGX) Stock Price Today
Key Stats
- $26.08BMarket Cap
- -Volume
- HealthSector
- $238.5052W High
- $173.4952W Low
- -Typical Hold Time
- $31.83BEnterprise Value
- 1.46%Div Yield
- -Trading Activity
Track Quest Diagnostics Inc (DGX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Quest Diagnostics Inc has traded between a low of $173.49 and a high of $241.76, highlighting its annual price range. Buy and sell Quest Diagnostics Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Most Recent News
PayPal may receive a higher takeover offer from Stripe and Advent, potentially $67–73 per share.
PayPal is reportedly in renewed takeover discussions with payment processor Stripe and private equity firm Advent International, with expectations of an improved acquisition offer. PayPal's large scale, including 439 million accounts and over $1.8 tr...
Chinese government bonds offer strong diversification as yields stay low amid domestic challenges.
Chinese government bonds remain attractive for investors seeking diversification due to their low yields and distinct behavior from global debt markets. While yields in the U.S., Japan, and the U.K. have surged, China's bonds benefit from a deflation...
Sionna Therapeutics shares plunge 92% after failed cystic fibrosis drug trial triggers shareholder lawsuit
Sionna Therapeutics' stock dropped 92% after its Phase 2a trial for cystic fibrosis drug SION-719 failed to meet key endpoints, notably reducing sweat chloride levels. This disappointing result has led shareholder rights firm Robbins LLP to investiga...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.